mixedAnecdotalMar 12, 2026
Self-reported side effects
Tirzepatide sentiment is heavily shaped by side-effect discussions, access issues, and comparisons with semaglutide communities.
arXivmedium confidencepreprint
Source Tirzepatide
Mounjaro · Zepbound
Weight LossApprovedApprovedPrescriptionSubQ
Popular for:Weight loss, type 2 diabetes, dual GIP/GLP-1 agonist
236
Registered Trials
122
Trial Publications
1,942
PubMed References
Approved
Evidence Level
Overview
Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly and marketed as Mounjaro (for type 2 diabetes) and Zepbound (for obesity). The short version: people usually care about it for weight loss, type 2 diabetes, dual gip/glp-1 agonist, but the strength of the evidence depends heavily on indication and study type.
Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly and marketed as Mounjaro (for type 2 diabetes) and Zepbound (for obesity). It is the first-in-class dual incretin agonist, and represents one of the most significant advances in obesity and diabetes treatment. It achieved up to 22.5% weight loss in Phase 3 trials.
**Originally developed for: **Type 2 diabetes (Mounjaro, FDA approved May 2022). Subsequently approved for chronic weight management (Zepbound, FDA approved November 2023).
Research Snapshot
What the evidence says
ApprovedTirzepatide currently shows 236 registered trials from ClinicalTrials.gov, 122 PubMed trial publications (111 RCT-tagged), and 1,942 PubMed references matching the stored source query. Treat PubMed references as literature surface area, not a count of clinical trials.
Known vs uncertain
Known signals
- 236 registered trials are tracked from ClinicalTrials.gov intervention records.
- 122 PubMed clinical-trial publications are indexed.
- 111 PubMed randomized controlled trial publications are indexed.
- 1,942 PubMed references are tracked separately from trial counts and can include animal, in-vitro, review, mechanism, or clinical records.
Open questions
- Evidence strength may vary by indication, route, formulation, and population.
- Public anecdotes can highlight interest or concern but do not establish clinical efficacy.
- Regulatory status and compounding access can change independently from the research literature.
Mechanism of Action
Tirzepatide activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors.
Key Research Benefits
Primary Benefits:
Superior weight loss — Up to 22.5% in Phase 3 trials, exceeding semaglutide (SURMOUNT-1, NEJM 2022)
Excellent glycemic control — HbA1c reductions of 2.0-2.6% in SURPASS trials
Cardiovascular risk reduction — SURPASS-CVOT showed 10% reduction in major adverse cardiovascular events
Improved lipid profile — Reduces triglycerides, improves HDL/LDL ratio
Secondary Benefits:
Blood pressure reduction
Liver fat reduction (being studied for MASLD/NAFLD)
Sleep apnea improvement (SURMOUNT-OSA trial showed significant AHI reduction)
Clinical Evidence Summary
Research Pipeline
Preclinical
Animal
Phase I
Phase II
Phase III
Approved
236
Registered Trials
122
Trial Publications
111
RCT Publications
1,942
PubMed References
ClinicalTrials.govPubMed ESearchExact-name queryChecked May 3, 2026
Registered trials are ClinicalTrials.gov intervention records. Trial publications are PubMed records tagged as clinical trials or randomized controlled trials. PubMed references are broader source-query matches and can include animal studies, in-vitro work, reviews, mechanism papers, and trial publications.
236
Registered trials
122
Trial publications
111
RCT publications
1,942
PubMed references
685
Reviews
115
Meta-analyses
Registered trials source
Jun 1, 2026
Tirzepatide
Uses the exact compound name as a ClinicalTrials.gov intervention query.
View source- SURPASS trials (1-5) — Comprehensive Phase 3 program for type 2 diabetes. Demonstrated superior HbA1c reduction vs. semaglutide, insulin degludec, and insulin glargine.
- SURMOUNT-1 (NEJM, 2022) — Phase 3 obesity trial. 2,539 participants. 15 mg dose: 22.5% weight loss at 72 weeks. One of the largest weight loss results ever seen in a clinical trial.
- SURMOUNT-OSA — Demonstrated significant improvement in obstructive sleep apnea severity.
- FAERS analysis (PMC, 2025) — Real-world safety data from FDA adverse event reporting. Confirmed known GI side effects as most common.
> Clinical trial status: FDA APPROVED. Mounjaro (type 2 diabetes, May 2022). Zepbound (chronic weight management, November 2023). Extensive Phase 3 data. Active post-marketing surveillance.
Key PubMed References
1,942 PubMed references · showing top 25 by relevance
View all on PubMedTirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Human Study
Aronne LJ, Horn DB, le Roux CW, et al. · The New England journal of medicine · 2025
PMID: 40353578Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
Human Study
Nicholls SJ, Pavo I, Bhatt DL, et al. · The New England journal of medicine · 2025
PMID: 41406444Tirzepatide for overweight and obesity management.
Review
Hamza M, Papamargaritis D, Davies MJ · Expert opinion on pharmacotherapy · 2025
PMID: 39632534Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation.
Human Study
Ravussin E, Sanchez-Delgado G, Martin CK, et al. · Cell metabolism · 2025
PMID: 40203836Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.
Human Study
Krüger N, Schneeweiss S, Fuse K, et al. · JAMA · 2025
PMID: 40886075Anecdotes & Sentiment
Public discussion, not clinical evidence
This section summarizes what people are talking about in public sources. It can be useful for spotting questions, hype cycles, and recurring concerns, but it is separate from the evidence sections above.
neutralAnecdotalMar 1, 2026
Side-effect reporting bias
Some users explicitly warn that online tirzepatide communities overrepresent side-effect posts because people without issues post less often.
Reddit / r/tirzepatidecompoundlow confidencereddit
Source Side Effects & Safety
**Common Side Effects:** - Nausea (most common, especially during titration — 12-33% in trials) - Diarrhea (12-23%) - Constipation - Decreased appetite (intended but can be excessive) - Injection site reactions **Rare but Serious Risks:** - Pancreatitis (GLP-1 class concern) - Thyroid C-cell tumors (boxed warning — based on rodent data) - Gallbladder disease — cholelithiasis with rapid weight loss - Hypoglycemia (when combined with insulin or sulfonylureas) > Boxed Warning: Thyroid C-cell tumors in rodents.
Common Side Effects:
Nausea (most common, especially during titration — 12-33% in trials)
Diarrhea (12-23%)
Constipation
Decreased appetite (intended but can be excessive)
Injection site reactions
Rare but Serious Risks:
Pancreatitis (GLP-1 class concern)
Thyroid C-cell tumors (boxed warning — based on rodent data)
Gallbladder disease — cholelithiasis with rapid weight loss
Hypoglycemia (when combined with insulin or sulfonylureas)
> Boxed Warning: Thyroid C-cell tumors in rodents. Contraindicated in personal/family history of medullary thyroid carcinoma or MEN2. Not for type 1 diabetes. Caution with history of pancreatitis. May delay absorption of oral medications.
Known Interactions
No curated interaction entry is live for Tirzepatide yet.
Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.
Comparison Pages
Frequently Asked Questions
Research Disclaimer
This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Regulatory status can vary by compound, formulation, indication, and jurisdiction. Check official labeling, registry records, and qualified professional guidance before making any health-related decision. The studies referenced are linked to their original PubMed sources for verification.